Here are the 10-K annual reports from Boundless Bio, Inc. (BOLD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLD filings page.
Boundless Bio, Inc. is a clinical-stage oncology company focused on cancers driven by extrachromosomal DNA (ecDNA), which it estimates occur in 14–17% of patients and are linked to poor survival and resistance to current therapies. Using its Spyglass discovery platform, the company designs small-molecule ecDNA-directed therapeutic candidates (ecDTx) that aim to exploit synthetic lethal vulnerabilities in ecDNA-positive tumors.
Lead candidate BBI-940, an oral degrader of a kinesin involved in DNA segregation, entered a Phase 1 first-in-human trial (KOMODO‑1) in February 2026 in ER+/HER2‑ metastatic breast cancer and TNBC‑LAR, with initial proof-of-concept data expected within the current cash runway. Boundless has discontinued development of CHK1 inhibitor BBI‑355 and RNR inhibitor BBI‑825 after a strategic portfolio review to prioritize BBI‑940. The company reports a limited operating history, expects significant losses for the foreseeable future, requires substantial additional capital, and highlights numerous clinical, regulatory, competitive, and listing risks. The aggregate market value of non‑affiliate common stock was approximately $18.0 million based on a $1.01 share price, and 22,407,251 common shares were outstanding as of March 2, 2026.